FDA Drug recall D-0616-2018
Fabior (tazarotene) Foam, 0.1%, 100 grams can, Rx only, Distributed by: Mayne Pharma, Greenville, NC 27834
- FDA Drug
- Class III
- terminated
- Published 2018-04-11
On 2018-04-11 the FDA classified a Class III recall of Fabior (tazarotene) Foam, 0.1%, 100 grams can, Rx only, Distributed by: Mayne Pharma, Greenville, NC 27834 by Mayne Pharma, citing superpotent Drug: High out of specification results for tazarotene assay at the 9-month stability time point.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0616-2018 |
| Classification | Class III |
| Status | terminated |
| Initiated | 2018-03-21 |
| Published | 2018-04-11 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Mayne Pharma |
| Distribution | US |
Product
Fabior (tazarotene) Foam, 0.1%, 100 grams can, Rx only, Distributed by: Mayne Pharma, Greenville, NC 27834; NDC 51862-295-10.
Reason
Superpotent Drug: High out of specification results for tazarotene assay at the 9-month stability time point.
Identifiers
| ndc | 51862-295-50 |
|---|---|
| ndc | 51862-295-10 |
| code_info | Lot: MBEB, Exp. 01/31/2019 |
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0616-2018%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.